Anticancer Drug Combinations, A Big Momentum is NeededLu DY1,2*, Chen EH2, Ding J2, Xu B2 and Lu TR3
- *Corresponding Author:
- Lu DY
School of Life Sciences
Shanghai University, Shanghai, China
Tel: +86 21 66163545
Fax: +821 66132177
E-mail: [email protected]
Received date: August 10, 2015; Accepted date: August 15, 2015 Published date: August 17,2015
Citation: Lu DY, Chen EH, Ding J, Xu B, Lu TR (2015) Anticancer Drug Combinations, A Big Momentum is Needed. Metabolomics 5:e139. doi: 10.4172/2153-0769.1000e139
Copyright: © 2015 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Most cancer therapies are seldom effective by using one anticancer drug owing to refractory and resistance
property of cancer tissues caused by multiple genetic alterations and molecular abnormalities. Despite great popularity of anticancer drug combination utilizations, the hidden rules behind scenarios emerge in new era of anticancer therapy. Most importantly, anticancer drug cocktails need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapy across the history. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated.